Apolipoprotein E Sendai (arginine 145 → proline): A new variant associated with lipoprotein glomerulopathy

Shinichi Oikawa, Akira Matsunaga, Takao Saito, Hiroshi Sato, Takafumi Seki, Katsuhiko Hoshi, Kyoko Hayasaka, Hidetoshi Kotake, Hiroshi Midorikawa, Akihiro Sekikawa, Susumu Hara, Keishi Abe, Takayoshi Toyota, Hisato Jingami, Haruki Nakamura, Jun Sasaki

Research output: Contribution to journalArticlepeer-review

87 Citations (Scopus)


Lipoprotein glomerulopathy (LPG) is a novel disease characterized by proteinuria, lipoprotein thrombi in the glomeruli, and increased concentration of plasma apolipoprotein (apo) E. It is believed that a genetic disorder of apo E may be present and associated with the disease. Three patients with LPG were examined in this study. The patients' DNA sequences were analyzed, and a nucleotide G to C point mutation in exon 4 of the apo E gene was confirmed in each patient. This missense mutation denotes amino acid substitution of the proline residue for arginine residue at position 145 of apo E. This variant (apo E Sendai) may cause a marked molecular conformational change of the apo E. These findings suggest that a novel variant is etiologically related to LPG.

Original languageEnglish
Pages (from-to)820-823
Number of pages4
JournalJournal of the American Society of Nephrology
Issue number5
Publication statusPublished - 1997 May

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Apolipoprotein E Sendai (arginine 145 → proline): A new variant associated with lipoprotein glomerulopathy'. Together they form a unique fingerprint.

Cite this